Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
In this study, we seek to explore the importance of fat accumulation in the kidneys in
relation to diabetic kidney disease (DKD). To do this, we conduct an intervention trial in
individuals with type 2 diabetes (T2D) and DKD where we investigate whether the inhibition of
intestinal cholesterol absorption with ezetimibe affects albuminuria (a strong risk factor
for diabetic complications) and kidney fat accumulation. At the same time and to confirm that
kidney fat accumulation is, in fact, abnormal in T2D and DKD, we conduct a cross-sectional
study in which we compare kidney fat accumulation in participants at baseline from the
intervention trial with a group of individuals with T2D and no DKD and a group of healthy
individuals.
Phase:
Phase 3
Details
Lead Sponsor:
Steno Diabetes Center Copenhagen
Collaborators:
Aase Handberg, professor, dr.med., Department of Clinical Biochemistry, Aalborg University Hospital Alessia Fornoni, MD PhD, Professor of Medicine, Chief, Katz Family Division of Nephrology and Hypertension Capital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark Department of Clinical Physiology, Nuclear Medicine and PET at Rigshospitalet Glostrup, Valdemar Hansens Vej 1-23, 2600 Glostrup, Denmark